1. Presurgical treatment of uterine myomas with the GnRH-antagonist relugolix in combination therapy: an observational study
- Author
-
Ludovico Muzii, Giulia Galati, Antonella Mercurio, Carlotta Olivieri, Letizia Scarcella, Ilham Azenkoud, Rossana Tripodi, Michele Vignali, Stefano Angioni, and Antonio Maiorana
- Subjects
Abnormal uterine bleeding ,Uterine myomas ,GnRH-antagonist ,Medical therapy ,Medicine ,Science - Abstract
Abstract To evaluate if a preoperative medical treatment with the GnRH-antagonist relugolix in combination therapy in a series of patients with abnormal uterine bleeding associated with uterine myomas may correct the anemia before scheduled surgery for myoma-associated AUB. Thirty-one patients scheduled for surgery underwent a pre-operative three-month course with a daily oral tablet of 40 mg relugolix, 1 mg estradiol, and 0.5 mg norethindrone acetate. Hemoglobin levels, uterine volumes, largest myoma diameter, and VAS score for dysmenorrhea, pelvic pressure and bleeding discomfort, and indication to surgery were evaluated at study enrollment and at the end of therapy. Mean hemoglobin levels increased by 25%, from 9.3 ± 1.1 to 11.6 ± 1.7 g/dL after three months (p
- Published
- 2024
- Full Text
- View/download PDF